Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout [Yahoo! Finance]
Immunic, Inc. (IMUX)
Company Research
Source: Yahoo! Finance
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named Michael A. Panzara as Chief Medical Officer, bringing aboard a veteran neurologist with more than 25 years of drug development experience as the biotechnology company braces for a critical clinical milestone in multiple sclerosis. Panzara will oversee clinical development, medical affairs, and regulatory affairs at the Nasdaq-listed company, which is developing vidofludimus calcium, an oral therapy targeting both immunological and neuroprotective pathways in MS patients. His appointment comes as Immunic prepares for the pivotal Phase 3 readout of its ENSURE trials in relapsing MS, a result the company expects within months. "Mike is a globally renowned biopharmaceutical executive and drug developer with deep expertise in neurology and proven leadership in advancing transformational therapies through development and the regulatory approval process," said CEO Daniel Vitt. Panzara arrives with an extensive track record in MS drug app
Show less
Read more
Impact Snapshot
Event Time:
IMUX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMUX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMUX alerts
High impacting Immunic, Inc. news events
Weekly update
A roundup of the hottest topics
IMUX
News
- Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer [TheStreet.com]TheStreet.com
- Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical OfficerPR Newswire
- Immunic to implement 1-for-10 reverse stock split [Yahoo! Finance]Yahoo! Finance
- Immunic announces 1-for-10 reverse stock split [Seeking Alpha]Seeking Alpha
IMUX
Earnings
- 11/13/25 - Beat
IMUX
Sec Filings
- 4/29/26 - Form 4
- 4/29/26 - Form 3
- 4/28/26 - Form 8-K
- IMUX's page on the SEC website